Remove Engineering Remove Patients Remove Physicians Remove Safety
article thumbnail

Leading patient adherence pharmaceutical companies

Pharmaceutical Technology

Failing to adhere to prescribed medication regimens is one of the prime reasons for poor patient health outcomes. Pharmaceutical and healthcare companies are working continuously to improve patient adherence, which also impacts disease control and pharmaceutical industry revenues directly. Patient adherence.

Leads 52
article thumbnail

8 Ways to Enhance the Patient Experience & Drive Leads with QR Codes

Healthcare Success

The QR code allows hospitals and healthcare providers to satisfy this need with immediate physician-patient interaction and engagement – all through smartphones and tablets. . Before we dive in, let’s discuss QR codes related to patient privacy and HIPAA compliance. . Placed strategically, the QR code does wonders for marketing.

Leads 109
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

UroMems Announces First-Ever Smart Artificial Urinary Sphincter Implant in a Female Patient

Legacy MEDSearch

UroMems , a global company developing innovative, mechatronics technology to treat stress urinary incontinence (SUI), announced today that it has successfully completed the first-ever implant of the UroActive smart, automated artificial urinary sphincter (AUS) in a female patient. Food and Drug Administration).

article thumbnail

Embracing the Power of Generative AI in Clinical Research

PM360

Accelerating Clinical Trial Timelines Notwithstanding our desire to speed important new medicines to patients in need, the planning, conduct, analysis and synthesis of programs of clinical research is a lengthy process. It speaks to medicine effectiveness and safety that scale and complement clinical trial data.

article thumbnail

China’s NMPA approves Daiichi Sankyo-AstraZeneca’s breast cancer therapy

Pharmaceutical Technology

Enhertu has received approval as a monotherapy to treat unresectable or metastatic HER2-positive breast cancer in adult patients who have previously received one or more anti-HER2-based regimens. Being jointly developed and commercialised by the two companies, it is a specifically engineered HER2-directed antibody-drug conjugate (ADC).

Safety 52
article thumbnail

15th Annual Pre-Filled Syringes and Injectable Drug Devices Conference

pharmaphorum

Explore updates to drug device combination product design approaches considering patient preference at the forefront with case studies from big pharma representatives. Eleanor Kimber, Principal Device Engineer, GSK. Markus Hemminger, Principal Medical Device Engineer, Roche. Petra Renne, Senior Expert Engineering, Novartis.

article thumbnail

How one pharma “family business” places patients first

pharmaphorum

And just as a family business thrives on its connection to the community, Chiesi is committed to connecting to the global patient community. We try to have a very long-term orientation because we believe that aligns our objectives very well with the objectives of society and the patients we serve, and it makes us a stable business.”.